



Published in final edited form as:

Org Lett. 2016 September 02; 18(17): 4174–4177. doi:10.1021/acs.orglett.6b01526.

## Total Synthesis of Macrocarpine D and E *via* an Enolate-Driven Copper-Mediated Cross-Coupling Process: Replacement of Catalytic Palladium with Copper Iodide

M. Toufiqur Rahman<sup>†</sup>, Jeffrey R. Deschamps<sup>‡</sup>, Gregory H. Imler<sup>§</sup>, Alan W. Schwabacher<sup>†</sup>, and James M. Cook<sup>†,\*</sup>

<sup>†</sup>Department of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, 3210 N. Cramer Street, Milwaukee, WI-53211, United States


<sup>‡</sup>Center for Biomolecular Science and Engineering, Naval Research Laboratory, Code 6930, Washington, D.C. 20375, United States

<sup>§</sup>ASEE Postdoctoral Fellow, Washington, DC 20036

### Abstract

An enolate driven copper-mediated cross-coupling process enabled a cheaper and greener access toward the key pentacyclic intermediates required for the enantiospecific total synthesis of a number of C-19 methyl substituted sarpagine/macroline indole alkaloids. Replacement of palladium (60–68%) with copper iodide (82–89%) resulted in much higher yields. The formation of an unusual 7-membered cross-coupling product was completely inhibited by using TEMPO as a radical scavenger. Further functionalization led to the first enantiospecific total synthesis of macrocarpine D and E.

### Graphical Abstract



The medicinal plants of the *Alstonia* (Apocynaceae) genus have been used in traditional medicine in many countries of the world from antiquity.<sup>1</sup> Their traditional uses include treatment of ulcers, dysentery, malaria, anthelmintics, diabetes, rheumatism, snake bites, etc.<sup>1</sup> The presence of indole alkaloids that are the secondary metabolites of these plants is the most probable source of their medicinal activity.<sup>2</sup> According to a review by Cordell et al. among the 60 plant-derived alkaloids of medicinal significance, 39 were directly related to their traditional uses.<sup>3</sup> Macroline/sarpagine type indole alkaloids are one of the major classes

\*Corresponding Author: capncook@uwm.edu.

#### Supporting Information Available

The Supporting Information is available free of charge on the ACS Publications website.

Experimental procedures and spectral data for **17**, **19**, **21**, **23** and **23'** as well as spectral data and <sup>1</sup>H and <sup>13</sup>C comparison tables between natural and synthetic **4** and **5** (pdf)

X-ray crystallographic data for **19**, **22**, **23**, and **23'** (cif)

of alkaloids isolated from these species to date by Le-Quesne, Elderfield, Schmid, Kam, and others.<sup>4–7</sup> Macrocarpine A–C (**1–3**) were isolated from the bark extract of *Alstonia macrophylla* in 2004.<sup>8</sup> Several other alkaloids of the same series, macrocarpine D (**4**) and macrocarpine E–H (**5–8**), were isolated in 2014 from the stem-bark and leaf extracts of *A. macrophylla* and *A. angustifolia* respectively by Kam et al.<sup>9,10</sup> All of these macroline type indole alkaloids, macrocarpine A–H (**1–8**) share the common feature of a  $\beta$ -methyl substituent at the C-19 position. This is a distinct difference from earlier *Alstonia* alkaloids isolated by LeQuesne and Schmid.<sup>5,7</sup> To date, around 30 alkaloids of the sarpagine/macroline/ajmaline family, which bear a diastereomeric methyl function at C-19 have been isolated.<sup>4,11</sup> Macroline related alkaloids *N*(4)-methyl-*N*(4),21-secotalpinine (**9**)<sup>8,12</sup>, *N*(4)-methyltalpinine (**10**)<sup>12</sup>, and 19-epitalcarpine (**11**)<sup>10</sup> as well as sarpagine related alkaloids macrosalpine chloride (**12**)<sup>13</sup>, and deoxyperaksine (**13**)<sup>14</sup> also possess the C-19 methyl substitution. Among these, **11** and **13** have a diastereomeric  $\alpha$ -methyl group at C-19. The synthesis of these alkaloids (**1–13**, Figure 1) has not been reported yet. Moreover, *N*(4)-methyltalpinine (**10**) and *N*(4)-methyl-*N*(4),21-secotalpinine (**9**) have been reported recently to have potent anticancer (NF- $\kappa$ B inhibitor, ED<sub>50</sub> 1.2  $\mu$ M) activity and profound leishmanicidal<sup>12</sup> activity, respectively. The unique structural features and potential medicinal properties prompted attempts at the first total synthesis of this class of alkaloids *via* a general strategy for the entire series. This is the basis of the approach toward chemical economy described here.

Copper-mediated carbon-carbon bond formation is more than a century old.<sup>15</sup> Although palladium-catalyzed cross-coupling reactions have been the dominant method in the field of total synthesis of complex natural products, copper has proven itself to be an essential alternative, as indicated by the increase in copper-mediated cross-coupling processes over the last decade.<sup>16</sup> As a result, it was decided to investigate a copper catalyzed, or mediated coupling process to offer a less expensive and less toxic alternative to catalytic palladium, while avoiding phosphine based ligands for easier purification. Moreover, potential improvements in yields, as well as workup and purification would be important.<sup>17</sup>

Wang et al.<sup>18</sup> developed an enolate driven palladium catalyzed  $\alpha$ -vinylation of a ketone in 2000 (Scheme 1, entry 1). This process has been employed in the total synthesis of several sarpagine/macroline/ajmaline indole alkaloids.<sup>19–21</sup> Although this palladium catalyzed process was effective in accessing the key intermediate **15** from vinyl iodide **14**, it provided only 60–68% yield in the case of vinyl iodides **16** or **18** (Scheme 1, entry 2), wherein there was a diastereomeric methyl function along with a terminal olefin in place of the ethylidene function in **14** (internal olefin, Wang, 2000). These features in **16** and **18** make them structurally and chemically different than **14**. Since the diastereomeric methyl function was essential for the synthesis of C-19 methyl substituted alkaloids, further improvement was required for better access to the key intermediates **17**, **19**, **21**, and **23**. More importantly, replacement of palladium with the cheaper and less toxic copper, would greatly facilitate use of this enolate-mediated process by others and formed much of the driving force in this research.

The copper-catalyzed conditions<sup>22</sup> that were used for the  $\alpha$ -vinylation of **14** gave lower yields along with an unusual, undesired product in the case of **22**. Numerous attempts were

made to optimize the desired yield of the olefin **23**, eliminate the unusual side product **23'** and understand the mechanism of multiple competing reactions. The implementation, improvement and extension of the scope of this process to access the C-19 methyl substituted sarpagine/macroline/ajmaline alkaloids with either an (*R*) or (*S*) C-19 methyl substituent in the  $N_a$ -H as well as  $N_a$ -CH<sub>3</sub> series (Scheme 1, entry 3) form the basis of this communication.

All of the vinyl iodide intermediates (**16**, **18**, **20** and, **22**) were prepared according to the previously reported procedures<sup>21</sup> (Scheme 2) beginning from the tetracyclic ketones **24/25** which had been prepared in the standard two pot process on 300 gram scale.<sup>23</sup> As depicted in Scheme 2, the  $N_b$  alkylation *via* S<sub>N</sub>2 substitution of the chiral tosylates (**26/27**) in CH<sub>3</sub>CN with K<sub>2</sub>CO<sub>3</sub> and subsequent deprotection of the TIPS protecting group with wet TBAF in THF furnished the  $N_b$ -alkylated terminal alkynes (**28–31**) in excellent yields. Haloboration<sup>21</sup> of the terminal alkynes with I-B(Cy)<sub>2</sub> in DCM followed by protodeboronation with HOAc, resulted in the vinyl iodides (**16**, **18**, **20**, and, **22**) in 74–79% yield with complete regioselectivity.

Initial experiments with vinyl iodide (**22**) and CuI under the reported conditions<sup>22</sup> resulted in the desired product (**23**) in lower yields (~42%) along with an unusual/unexpected cyclization product (**23'**), a seven-membered ring with an internal alkene (Scheme 3).

The structures of both the desired (**23**) and unexpected seven-membered ring (**23'**) cross-coupling products have been confirmed by MS, 1D and 2D NMR, and X-ray crystallographic analysis (see Supporting Information (SI) for details). In the absence of CuI, the same conditions yielded the 7-membered product to a greater extent. Increasing the equivalents of CuI and ligand to 1.0 equivalent and the base to 4.0 equivalents (entry 3 of Table 1) resulted in a higher overall yield of the desired material (67%), while the unexpected product was still present (~21%).

It was not surprising that this series of vinyl iodides (**16**, **18**, **20** and, **22**) would have different reactivities than vinyl iodides reported earlier.<sup>18</sup> Differences in the substrates included the presence of a methyldiene (a terminal alkene) instead of the ethyldiene in **14** (an internal alkene) as well as the presence of the chiral methyl function at C-19 instead of an achiral methylene. In order to rationalize this unprecedented seven-membered ring cyclization, it was felt that a radical mechanism may have been involved in its formation. To test this hypothesis, it was decided to use 2,2,6,6-tetramethylpiperidinyl-1-oxy (TEMPO), the well-known radical scavenger<sup>24</sup>, to inhibit any radical step or species that may have diverted the mechanism. In support of this hypothesis, an experiment with 2.5 equivalents of TEMPO (entry 5 of Table 1) resulted in almost complete inhibition of the formation of the undesired 7-membered internal alkene (~3% by NMR spectroscopy) with 45% overall yield of **23**. Increasing the amount of TEMPO to 3.0 equivalents completely eliminated the undesired cyclization (see SI) and provided the desired cross-coupling product **23** in 66% yield. After many experiments by changing reaction parameters and screening different copper sources (entries 8–15 of Table 1) the optimized condition was found to be 1.0 equiv of CuI, 1.0 equiv of ligand, 4.0 equiv of Cs<sub>2</sub>CO<sub>3</sub>, and 3.0 equiv of TEMPO. This combination furnished 89% yield of the desired cross-coupled product to the exclusion of

the 7-membered byproduct as compared to (60–68%) with a palladium catalyst.<sup>21,25</sup> This modified reaction condition was effective for both stereoisomers of the C-19 methyl substitution and in both the  $N_a$ -H and  $N_a$ -CH<sub>3</sub> series (**16**, **18**, **20** and **22**) as well. This permitted the application of this Cu-mediated cross-coupling process to access the key intermediates (**17**, **19**, **21** and **23**) in gram-quantities toward all of the macroline/sarpagine alkaloids discussed above (Scheme 4). While TEMPO was initially chosen as a radical probe, the reason for its useful effect is under investigation.

Surprisingly, it was observed that the base Cs<sub>2</sub>CO<sub>3</sub> alone in DMF (entry 2 of Table 1) could yield both of the products in an approximately 2 to 1 ratio. This observation indicated the possibility of another competing mechanism wherein the vinyl iodide (**22**) or intermediate underwent an E-2 like elimination or radical process to produce a terminal alkyne (**31**, *in situ*). This alkyne subsequently could undergo a 6-(*enolendo*)-*exo-dig* (process A in Scheme 5) which would produce the six-membered external alkene (**23**) as a major product and a 7-(*enolendo*)-*endo-dig* cyclization (process B in Scheme 5) to produce the seven-membered internal alkene (**23'**) as the minor product (Scheme 5). Both of these processes are allowed by Baldwin's rules for ring closure.<sup>26,27</sup> This hypothesis has been confirmed by stopping the reaction (at 3 hours) before completion. The alkyne **31** was detected along with traces of the cross-coupling products **23** and **23'**.

The investigation of the competing mechanisms is now ongoing; however, gratifying excellent yields (82–89%) of only the desired six-membered ring were obtained in a stereospecific fashion with copper iodide (Scheme 4).

With the pentacyclic ketones in hand, in excellent yields, the total synthesis of a series of C-19 methyl substituted sarpagine macroline indole alkaloids was undertaken, which included the potent anticancer alkaloid, *N*(4)-methyltalpinine (**10**), as well as the leishmanicidal base (**9**), macrocarpines A–G (**1–7**), and, deoxyperaksine (**13**). Herein is reported the first total synthesis of the  $N_a$ -H bearing macroline indole alkaloids macrocarpine D (**4**) and E (**5**) (Scheme 6, 7).

The pentacyclic ketone (**17**) was subjected to a one-carbon homologation *via* Wittig olefination using methoxymethyl trip-henylphosphonium chloride and potassium *tert*-butoxide in benzene to furnish the enol ether, which was hydrolyzed without purification to aldehyde (**32**) under acidic conditions (Scheme 6). The aldehyde was isolated in the stable  $\alpha$  position even in the presence of the C-19  $\beta$ -methyl group. The aldehyde (**32**) was reduced to alcohol (**33**) with sodium borohydride in ethanol and subsequently protected with a TIPS group to give the silyl ether (**34**). The alkene (**34**) was subjected to hydroboration (borane dimethyl sulfide) and Kabalka oxidation (NaBO<sub>3</sub>) to provide primary alcohol (**35**) in 73% yield. Oxidation of the primary alcohol under Corey-Kim conditions at –78 °C produced a mixture of  $\alpha$  and  $\beta$ -aldehydes with the  $\alpha$  isomer as the major product. This mixture was epimerized entirely to the  $\alpha$ -aldehyde (**36**) with Et<sub>3</sub>N in methanol added to the mixture.

Quaternization of the  $N_b$ -group with iodomethane in methanol gave the iodide salt (**37**, Scheme 7). The quaternary ammonium salt underwent *retro*-Michael ring opening in the

presence of NaHMDS in THF to produce the  $\alpha,\beta$ -unsaturated aldehyde (**38**) in 78% yield similar to the work first reported by LeQuesne.<sup>5</sup>

The TIPS group was removed by heating **38** under mild acidic conditions in THF. The so formed alcohol added in Michael fashion to the  $\alpha,\beta$ -unsaturated aldehyde to produce (**39**) and (**40**) as an epimeric mixture of aldehydes with the  $\beta$ -methyl group. Each of these could be isolated by silica gel flash chromatography. The desired aldehydes (**39**) and (**40**) upon reduction with sodium borohydride in ethanol gave macrocarpine E (**5**) and macrocarpine D (**4**) in 96% and 92% yield, respectively. Spectroscopic data and optical rotations of the synthetic products are in complete agreement with natural macrocarpine D & E. The total synthesis of the other alkaloids of interest is ongoing.

In summary, the first total synthesis of macrocarpine D (**4**) and E (**5**) has been accomplished *via* a key copper-mediated cross-coupling process toward the important intermediates. This general strategy enables one to access all of the indole alkaloids of the same class with stereospecific incorporation of the important  $\beta$  (or  $\alpha$ )-methyl function at C-19. Replacement of the palladium catalyst with CuI provides a much more useful and cheaper method since the copper catalyst, even at stoichiometric amounts, is much cheaper than catalytic palladium (see SI for a comparative price table). More importantly, accessing **17** in 83% yield with copper compared to 60% with catalytic palladium serves as an example of replacement of palladium in this enolate-mediated process which makes it much more useful for others, especially in the pharmaceutical industry.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

We gratefully acknowledge support from the National Institutes of Health (MH096463; HL118561) and the Shimadzu Analytical Laboratory of Southeastern Wisconsin.


## References

1. Khyade MS, Kasote DM, Vaikos NPJ. *J Ethnopharmacol.* 2014; 153:1. [PubMed: 24486598]
2. Ziegler J, Facchini PJ. *Annu Rev Plant Biol.* 2008; 59:735. [PubMed: 18251710]
3. Cordell GA, Quinn-Beattie ML, Farnsworth NR. *Phytother Res.* 2001; 15:183. [PubMed: 11351353]
4. Namjoshi, OA., Cook, JM. *The Alkaloids: Chemistry and Biology.* Knölker, H-J., editor. Vol. 76. Academic Press; San Diego, CA: 2016. p. 63
5. Garnick RL, Le Quesne PW. *J Am Chem Soc.* 1978; 100:4213.
6. Elderfield RC, Gilman RE. *Phytochemistry.* 1972; 11:339.
7. Kishi T, Hesse M, Gemenden C, Taylor W, Schmid H. *Helv Chim Acta.* 1965; 48:1349. [PubMed: 5846758]
8. Kam T-S, Choo Y-M, Komiyama K. *Tetrahedron.* 2004; 60:3957.
9. Lim S-H, Low Y-Y, Sinniah SK, Yong K-T, Sim K-S, Kam T-S. *Phytochemistry.* 2014; 98:204. [PubMed: 24342109]
10. Tan S-J, Lim J-L, Low Y-Y, Sim K-S, Lim S-H, Kam T-S. *J Nat Prod.* 2014; 77:2068. [PubMed: 25211145]

11. Lounasmaa, M., Hanhinen, P., Westersund, M. The Alkaloids: Chemistry and Biology. Cordell, GA., editor. Vol. 52. Academic Press; San Diego, CA: 1999. p. 103
12. Pan L, Terrazas C, Acuña UM, Ninh TN, Chai H, de Blanco EJC, Soejarto DD, Satooskar AR, Kinghorn AD. *Phytochem Lett.* 2014; 10:54. [PubMed: 25584095]
13. Khan ZM, Hesse M, Schmid H. *Helv Chim Acta.* 1967; 50:1002. [PubMed: 5592024]
14. Iwu M. *Planta Med.* 1982; 45:105. [PubMed: 17396795]
15. Ullmann F, Bielecki J. *Ber Dtsch Chem Ges.* 1901; 34:2174.
16. Evano G, Blanchard N, Toumi M. *Chem Rev.* 2008; 108:3054. [PubMed: 18698737]
17. Beletskaya IP, Cheprakov AV. *Coord Chem Rev.* 2004; 248:2337.
18. Wang T, Cook JM. *Org Lett.* 2000; 2:2057. [PubMed: 10891229]
19. Zhao S, Liao X, Wang T, Flippen-Anderson J, Cook JM. *J Org Chem.* 2003; 68:6279. [PubMed: 12895062]
20. Edwankar CR, Edwankar RV, Deschamps JR, Cook JM. *Angew Chem, Int Ed.* 2012; 51:11762.
21. Edwankar RV, Edwankar CR, Deschamps JR, Cook JM. *J Org Chem.* 2014; 79:10030. [PubMed: 25247616]
22. Yin W, Kabir MS, Wang Z, Rallapalli SK, Ma J, Cook JM. *J Org Chem.* 2010; 75:3339. [PubMed: 20392128]
23. Yu P, Wang T, Li J, Cook JM. *J Org Chem.* 2000; 65:3173. [PubMed: 10814213]
24. Wright PJ, English AM. *J Am Chem Soc.* 2003; 125:8655. [PubMed: 12848573]
25. Edwankar RV, Edwankar CR, Deschamps J, Cook JM. *Org Lett.* 2011; 13:5216. [PubMed: 21877687]
26. Baldwin JE, Lusch MJ. *Tetrahedron.* 1982; 38:2939.
27. Baldwin J. *Chem Soc, Chem Commun.* 1976:734.




**Figure 1.**  
Examples of some C-19 methyl substituted sarpagine/macroline indole alkaloids


**Scheme 1.**

Regiospecific access to the pentacyclic core system *via* palladium and copper-catalyzed cross-coupling process




**Scheme 2.**


Completely Regioselective access to the vinyl iodides 16, 18, 20, and 22

**Scheme 3.**


Enolate driven copper mediated cross-coupling of the vinyl iodide (22)

**Scheme 4.**


Access to the key pentacyclic ketone intermediates 18, 20, 22 and, 24 *via* the optimized conditions

**Scheme 5.**

Possible mechanism for the observed base mediated cyclization (Table 1 entries 2 and 4)



**Scheme 6.**  
Toward macrocarpine D (4) and E (5) from the key intermediate 17



**Scheme 7.**  
Total synthesis of macrocarpine D (4) and E (5)

Table 1

Optimization of reaction conditions for the Cu-mediated cross-coupling reaction of 22

entry	CuI or cat.	L	Cs <sub>2</sub> CO <sub>3</sub>	scv.	23:23' (by NMR) <sup>a</sup>	overall yield (%) <sup>b</sup>
1	0.5	0.5	2.0	–	89:11	47
2	–	0.5	2.0	–	63:37	45
3	<b>1.0</b>	<b>1.0</b>	<b>4.0</b>	–	<b>79:21</b>	<b>67</b>
4	–	–	2.0	–	64:36	35
5	0.5	0.5	2.0	2.5	97:3	45
6	<b>0.5</b>	<b>0.5</b>	<b>2.0</b>	<b>3.0</b>	<b>100:0</b>	<b>66</b>
7	<b>1.0</b>	<b>1.0</b>	<b>4.0</b>	<b>3.0</b>	<b>100:0</b>	<b>89</b>
8	0.1	0.1	4.0	3.0	100:0	25
9	0.5	0.5	4.0	3.0	100:0	40
10	1.0	–	4.0	3.0	100:0	11
11	1.0	1.0	–	3.0	–	ND <sup>c</sup>
12	–	1.0	4.0	3.0	–	ND
13	cat.-2 (1.0)	1.0	4.0	3.0	100:0	51
14	cat.-3 (1.0)	1.0	4.0	3.0	100:0	24
15	cat.-4 (1.0)	1.0	4.0	3.0	100:0	28

Unit for all reagent amounts is equivalent (equiv); scv. = TEMPO scavenger

<sup>a</sup>Ratio determined by <sup>1</sup>H NMR spectroscopy

<sup>b</sup>Overall isolated yield after flash chromatography on neutral alumina

<sup>c</sup>Starting material was recovered; ND = not detected; L = *cis*-1,2-cyclo-hexanediol; cat.-2 = Cu(CH<sub>3</sub>CN)<sub>4</sub>OAc; cat.-3 = Cu(CH<sub>3</sub>CN)<sub>4</sub>ClO<sub>4</sub>; cat.-4 = Cu(CH<sub>3</sub>CN)<sub>4</sub>OTf (see SI for detailed experimental procedures)